Taking Wegovy for 3 months: what the evidence actually shows

What the trial data says about the 12-week point

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Average weight loss at the end of the study was around 15% of starting body weight on semaglutide 2.4mg. That figure was not achieved at three months. The trial's own trajectory shows weight loss continuing to accumulate well past week 12, with the curve still descending at 20 and 40 weeks before beginning to plateau.

Three months into treatment, the majority of participants were only just completing their dose escalation. The Wegovy schedule starts at 0.25mg weekly and increases in steps roughly every four weeks, reaching the 2.4mg maintenance dose around week 16 to 20. That means a 12-week course typically ends before a person has spent a single week at full dose. The evidence base for Wegovy's effectiveness is built on maintenance-dose exposure over many months, not starter-dose exposure over a few.

This is a question our prescribers hear most weeks, usually from people who want to plan ahead or who are weighing up cost. The honest clinical answer is that three months is a reasonable time to assess tolerability and early response, but it is too short a window to judge the medicine's full effect.

Why stopping at 3 months changes the outcome

The evidence on what happens after discontinuation is clear. A follow-up to the STEP 1 programme found that participants who stopped semaglutide regained a substantial portion of the weight they had lost within a year of stopping, alongside partial return of the cardiometabolic improvements seen during treatment. The medicine works while you take it; weight management is an ongoing process, not a course with a fixed end date.

NICE's guidance on semaglutide (Wegovy) in technology appraisal TA875 recommends reviewing continuation at six months on the maintenance dose, not at three months. At that point, the question is whether at least 5% of body weight has been lost. Three months into treatment, most people have not yet reached the maintenance dose, let alone spent six months there. Stopping at week 12 means the clinical review point recommended by NICE has not yet arrived.

None of this means three months is worthless. Early progress is real, and for people who experience significant side effects or for whom the medicine is clinically unsuitable, stopping sooner is the right call. The point is that three months is rarely a natural endpoint for people who are tolerating treatment well and seeing results. What happens at the three-month mark is better understood as a milestone than a finish line.

What a longer course typically involves

Most people who continue beyond three months spend the following weeks establishing themselves at the 2.4mg maintenance dose and then working through the phase where weight loss is most pronounced. The six-month point is where NICE says the first formal continuation decision should be made, and many people find their results look quite different by then compared to week 12.

The licensed indication for Wegovy is weight management alongside a reduced-calorie diet and increased physical activity. It is not a short-term intervention by design. That said, NICE TA875 does specify a maximum of two years under NHS prescribing within a specialist weight management service. Private prescribing follows the licensed SmPC and individual clinical assessment rather than that two-year NHS commissioning ceiling, and the right duration for any individual is a conversation between patient and prescriber based on response, tolerability and health goals.

If you are comparing the cost of different durations, the UK price landscape for Wegovy is worth understanding before you decide, what treatment costs per month changes with dose, and a full picture helps with planning. The treatment page at weight-loss-treatments covers how a private consultation works if you want to explore this with a prescriber.

What to look for at three months if you are already on treatment

Three months in is a genuinely useful checkpoint. Tolerability should be clearer by now; most GI side effects are most noticeable in the early weeks and settle as the body adjusts, as the NHS semaglutide medicines page notes. You will also have a clearer sense of how the dose escalation is going and whether you are responding as hoped.

Early weight loss at three months does tend to predict longer-term response, so this is a reasonable moment to review progress with your prescriber. It is not, however, a reliable moment to conclude that treatment has done what it can. If you started at two months finding nausea manageable and are now at three months with appetite noticeably reduced, that pattern typically continues and builds over the following months, as people who have written about reaching the four-month stage on Wegovy often describe. Decisions about month five and beyond are best made in that context, with a prescriber who knows your history, not based on an arbitrary 12-week target set before treatment began.

Wegovy is a prescription-only medicine. If you are considering starting, or want clinical guidance on how long a course makes sense for your circumstances, a free consultation with one of our GPhC-registered prescribers is the right first step.